Bayer AG
BAYZF
Market Cap$21.61B
Close$
Earnings Call Q3 2024
November 12, 2024 - AI Summary
Overall Performance and Guidance for 2024: Bayer is on track to meet its full-year targets for sales growth, core earnings per share (EPS), free cash flow, and net debt, despite facing a challenging agriculture market with an expected decline of around 2%. Pharmaceuticals and Consumer Health are performing well, compensating for slowdowns in Crop Science.
Pharmaceuticals Growth and Upcoming Launches: The Pharmaceuticals division grew 2% YoY to €4.5 billion in Q3, driven mainly by strong performance from launch assets like Nubeqa, which reached blockbuster status with nearly €1.1 billion in sales for the first nine months. The division is projecting continued growth momentum into 2025 with upcoming launches of Acoramidis and Elinzanetant.
Challenges in Crop Science: Crop Science is expected to have lower sales, with adjustments leading to a decline of 3% to 1% for 2024 due to adverse weather conditions in Latin America, disease pressures, and generic pricing challenges. Regulatory issues, including concerns over dicamba registration, further complicate outlook, with potential impacts on EBITDA margin of 200 to 300 basis points.
Exclusive for Stockcircle Pro members
Sign up
Share Statistics
| Market cap | $21.61 Billion |
|---|---|
| Enterprise Value | $17.90 Billion |
| Dividend Yield | $- (-%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0.38 |
| Enterprise Value to EBIT | 5.25 |
| Enterprise Value to Net Income | -21 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Bayer AG
CEO: Werner Baumann Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. It operates through the following segments: Pharmaceuticals, Consumer Health, Crop Science, Ani...